“…In cancer cells, β1 integrins are associated with proliferative signaling, trigger cell death resistance, induce angiogenesis and activate cell migration and the metastatic cascade [35,36,37,38,39]. β1 integrins contribute to chemotherapy resistance [38,40,41,42,43,44,45,46,47,48,49,50] and promote radiotherapy resistance in HNSCC [51,52,53,54], breast carcinoma [55,56], laryngeal carcinoma [57,58], and glioma [59,60]. Based on these observations, β1 integrin antagonists such as small molecules (ATN-161, JSM6427) or function-blocking antibodies (volociximab, OS2966) have been considered as potential therapeutic approaches [32].…”